GES

Gemoscan Canada, Inc. ("Gemoscan" or the "Corporation") (TSX VENTURE:GES)
(MUN:1GE) wishes to announce that it is offering up to $500,000 in convertible
debentures. The debentures will have a term of one (1) year and pay interest at
the rate of 8% per annum. The debentures will be unsecured. The debentures will
be convertible into shares of the Corporation at the rate of one Class A share
for each $0.27 converted. In addition, purchasers shall receive one-half of a
share purchase warrant for each $0.27 in debenture acquired Each full warrant
will entitle the holder to acquire a Class A share at a price of $0.27 per share
for a period of one year. 


All securities issued pursuant to the above referenced private placements are
subject to a statutory four month hold period and regulatory approval.


The proceeds from the offering will be used for working capital purposes.

The TSX Venture Exchange has conditionally approved the offering which is
scheduled to close on August 15, 2012.


ABOUT GEMOSCAN CANADA, INC.

Founded in 2003 Gemoscan owns and markets the HEMOCODE(TM) Food Intolerance
System, a personalized well-being nutritional program that uses its own patented
technology and services to detect and provide recommendations for the management
of immuno-based food sensitivities. The HEMOCODE(TM) Food Intolerance System was
designed to take the guesswork out of deciphering what variety of common foods
and additives may potentially offend and adversely affect personal wellness.
Customer-specific reports, nutritional guidelines and recipe books are
accompanied by consultation with health-care specialists.


Forward-Looking Information

This news release contains certain "forward-looking information". All
statements, other than statements of historical fact, that address activities,
events or developments that Gemoscan believes, expects or anticipates will or
may occur in the future. These forward-looking statements reflect the current
expectations or beliefs of Gemoscan based on information currently available to
Gemoscan. Forward-looking statements are subject to a number of significant
risks and uncertainties and other factors that may cause the actual results of
Gemoscan to differ materially from those discussed in the forward-looking
statements, and even if such actual results are realized or substantially
realized, there can be no assurance that they will have the expected
consequences to, or effects on Gemoscan. Any forward-looking statement speaks
only as of the date on which it is made and, except as may be required by
applicable securities laws, Gemoscan disclaims any intent or obligation to
update any forward-looking statement, whether as a result of new information,
future events or results or otherwise. Although Gemoscan believes that the
assumptions inherent in the forward-looking statements are reasonable,
forward-looking statements are not guarantees of future performance and
accordingly undue reliance should not be put on such statements due to the
inherent uncertainty therein.

Gemoscan Canada, Inc. (TSXV:GES)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Gemoscan Canada, Inc. (TSXV:GES)
Historical Stock Chart
Von Jun 2023 bis Jun 2024